Long QT, Brugada, and CPVT: Sudden Death in Hearts That Look Normal

A 17-year-old swimmer collapses at the end of a high school meet. Bystander CPR and a deployed AED save her life. In the hospital, the echocardiogram is normal. The cardiac MRI is normal. The coronaries on CT angiography are pristine. By every structural measure, her heart is fine. But her resting EKG shows a QTc of 510 milliseconds, and her mother and aunt have a history of unexplained syncope during exercise. The diagnosis: long QT syndrome, type 1.

I'm Dr. Damian Rasch, a cardiologist in Encinitas. Channelopathies are inherited disorders of the heart's electrical machinery, the ion channels that govern how the heart's electrical impulse forms and propagates. The hearts of patients with these conditions are structurally normal. They squeeze fine, fill fine, and look fine on imaging. But under the right conditions (a specific trigger, a specific medication, a specific environment), the electrical system fails catastrophically and produces a lethal arrhythmia. This article walks through the three most clinically important channelopathies: long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT). The reason these matter is that they are diagnosable, treatable, and screenable in family members, and a missed diagnosis can be a sudden death event that should never have happened.

The Common Thread: Ion Channel Disease

Every heartbeat depends on the coordinated movement of ions (sodium, potassium, calcium) across the membranes of cardiac myocytes. Specialized protein channels open and close in precise sequence to produce the action potential, the electrical wave that triggers contraction. When the genes that code for these channels are mutated, the action potential is altered. The mutation might prolong it, shorten it, destabilize it, or make it vulnerable to certain triggers. The result is a heart that conducts electricity normally most of the time but becomes arrhythmically unstable under stress.

The three channelopathies covered in this article share several features. All are inherited, mostly in autosomal dominant patterns. All produce structurally normal hearts on imaging. All carry a risk of sudden cardiac death from ventricular arrhythmias. All have specific clinical patterns that, once recognized, allow for diagnosis, treatment, and family screening. And all benefit from being caught before the first cardiac event, which is why patient education and clinical recognition matter so much.

Long QT Syndrome

Long QT syndrome is the most common inherited channelopathy, with an estimated prevalence of about 1 in 2,000 to 5,000 people. The defining feature is a prolonged QT interval on the EKG, which represents prolonged ventricular repolarization. When repolarization takes too long, the ventricles become vulnerable to a chaotic, polymorphic ventricular tachycardia called torsades de pointes, which can degenerate into ventricular fibrillation and cause sudden death.

The Three Main Genetic Subtypes

More than fifteen genetic subtypes of long QT have been identified, but three account for the vast majority of cases.

LQT1 is caused by mutations in KCNQ1, which codes for the slow-delayed rectifier potassium channel (IKs). Patients with LQT1 have arrhythmic events almost exclusively during exercise, especially swimming and physical exertion. Swimming is the most distinctive trigger; an unexplained near-drowning or drowning in someone who knows how to swim should always raise suspicion for LQT1. Beta-blockers, especially nadolol, are remarkably effective in LQT1, with a roughly 70 to 80 percent reduction in arrhythmic events on adequate therapy.

LQT2 is caused by mutations in KCNH2 (also called HERG), which codes for the rapid-delayed rectifier potassium channel (IKr). Patients with LQT2 have events triggered by emotional stress, sudden auditory stimuli (like an alarm clock or a phone ringing), and the postpartum period. The auditory trigger is so distinctive that an alarm clock that produces a sudden tone is sometimes the precipitant. Beta-blockers help in LQT2, but the protection is less complete than in LQT1, and many LQT2 patients also need an implantable cardioverter-defibrillator. The hERG channel is also the target of many medications that prolong the QT interval, which means patients with LQT2 are at especially high risk from QT-prolonging drugs.

LQT3 is caused by mutations in SCN5A, which codes for the cardiac sodium channel. Unlike LQT1 and LQT2, LQT3 events tend to occur at rest or during sleep, when sympathetic tone is low and parasympathetic tone dominates. This is the inverse of the LQT1 pattern. Sodium channel blockers, especially mexiletine, can shorten the QT interval and reduce arrhythmic risk in LQT3, in addition to beta-blockers and an ICD for high-risk patients.

Knowing the genetic subtype matters because the triggers and the treatment differ. A patient with LQT1 needs to be careful about exercise, especially swimming, and may benefit from a different beta-blocker dose schedule. A patient with LQT2 needs to avoid the long list of QT-prolonging medications and should consider not having sudden auditory triggers in the bedroom. A patient with LQT3 needs sodium channel-targeted therapy beyond beta-blockers.

Diagnosis

The starting point is the resting 12-lead EKG with a careful measurement of the QT interval, corrected for heart rate using Bazett's formula or other correction methods. A QTc greater than 460 milliseconds in adult women or 450 milliseconds in adult men is considered prolonged. A QTc greater than 480 milliseconds is suggestive, and greater than 500 milliseconds is concerning. The Schwartz score combines EKG findings, clinical history, and family history to estimate the probability of long QT syndrome and is used to guide the workup.

Exercise stress testing is helpful because LQT1 patients often show a characteristic prolongation of QT during early recovery from exercise. The QT also fails to shorten appropriately during peak exercise. Holter monitoring can capture arrhythmic events and the QT response to daily activities.

Genetic testing is now a standard part of the long QT workup when the diagnosis is suspected on clinical grounds. A positive genetic test confirms the diagnosis and identifies the subtype, which guides treatment. A negative genetic test does not rule out long QT syndrome (only about 70 to 80 percent of clinically diagnosed patients have an identifiable mutation), but it can simplify family screening when a mutation is identified in the index patient.

Treatment

Beta-blockers are the foundation of long QT treatment. Nadolol, taken once or twice daily, is the most effective and most studied. Propranolol is an alternative. Metoprolol and atenolol are used in some cases but appear to be less protective than nadolol in head-to-head studies. Doses are titrated to control symptoms and to ensure adequate beta-blockade during exercise. Compliance matters enormously, since the protection wanes within a day or two of stopping the medication.

Lifestyle modification is part of every long QT plan. Avoidance of QT-prolonging medications is critical. The list is long and includes many antibiotics (azithromycin, levofloxacin, moxifloxacin), antifungals (fluconazole), antipsychotics (haloperidol, ziprasidone), antidepressants (citalopram at higher doses), antiemetics (ondansetron), and others. CredibleMeds.org maintains a current list that patients should consult before starting any new medication. Avoidance of dehydration and electrolyte abnormalities (low potassium, low magnesium) matters because these can prolong QT further. Specific subtype-related precautions: avoiding swimming alone in LQT1, removing sudden auditory triggers in LQT2.

An implantable cardioverter-defibrillator is recommended for patients who have had a cardiac arrest, who continue to have syncope despite optimal beta-blocker therapy, or who have very high-risk features (extremely prolonged QTc, certain genetic variants, family history of sudden death). The device terminates ventricular fibrillation when it occurs, providing a backup for patients whose risk can't be fully reduced with medication alone.

Left cardiac sympathetic denervation, in which the surgeon disrupts the sympathetic nerves to the heart on the left side, is an option for patients with refractory disease despite beta-blockers and an ICD. It markedly reduces arrhythmic burden in selected patients.

Brugada Syndrome

Brugada syndrome is less common than long QT, with an estimated prevalence of about 1 in 2,000 to 5,000 in some populations and higher in Southeast Asian populations. The defining feature is a characteristic EKG pattern in the right precordial leads (V1 to V3), with sudden cardiac death typically occurring during sleep or rest, often in young men.

Genetics and Mechanism

About 25 percent of Brugada patients have a mutation in SCN5A, the same gene involved in LQT3. Other mutations have been identified in calcium channel genes and others, but the genetic landscape is more complex than long QT, and many Brugada patients don't have an identifiable mutation. The functional defect is reduced sodium current, which produces an imbalance during phase 1 of the action potential in the right ventricular outflow tract, the area where the diagnostic EKG pattern shows up.

The EKG Patterns

Three EKG patterns have been described, but only the Type 1 pattern is diagnostic. The Type 1 pattern shows coved ST-segment elevation of at least 2 millimeters in V1 and V2, with the elevated segment descending into a negative T wave. The other patterns (Type 2 with saddleback morphology, Type 3 with smaller saddleback) are suggestive but not diagnostic on their own.

The Type 1 pattern can be intermittent. A patient might have a normal EKG one day and a Type 1 pattern the next. Several triggers can unmask the pattern, including fever, sodium channel-blocking medications, and certain drugs of abuse like cocaine. The diagnosis is sometimes made when an EKG done during a febrile illness shows the diagnostic pattern that wasn't apparent when the patient was well.

Provocation testing with intravenous sodium channel blockers (procainamide or ajmaline) can unmask a Type 1 pattern in patients with suggestive but non-diagnostic baseline EKGs and a clinical concern for Brugada syndrome. This is done in a monitored cath lab or electrophysiology setting because the test can sometimes precipitate the very arrhythmia we're trying to identify.

Risk Stratification and Treatment

Brugada syndrome is one of the more challenging channelopathies to risk stratify because many patients with the EKG pattern never have an arrhythmic event, while others have sudden death as the first manifestation. The strongest predictors of arrhythmic risk are a history of resuscitated cardiac arrest, a history of unexplained syncope thought to be cardiac in origin, and a spontaneous Type 1 pattern (rather than a drug-induced one). Family history of sudden cardiac death and certain genetic features add to the risk profile.

Patients with a history of cardiac arrest or syncope thought to be arrhythmic should receive an implantable defibrillator. Asymptomatic patients with only a drug-induced Type 1 pattern, no syncope history, and no family history of sudden death are usually managed without an ICD, with careful follow-up and avoidance of triggers.

Lifestyle interventions for Brugada include aggressive treatment of fever (acetaminophen at the first sign of fever, since fever can trigger the diagnostic pattern and arrhythmias), avoidance of sodium channel blockers (a long list including some antiarrhythmic medications, certain antidepressants, lithium, and others), avoidance of large meals (which can transiently trigger arrhythmias in some patients through increased vagal tone), and avoidance of cocaine and excessive alcohol.

Quinidine, an older antiarrhythmic medication that blocks the transient outward potassium current (Ito), can suppress arrhythmias in some Brugada patients and is sometimes used as adjunctive therapy or as an alternative to ICD in patients who decline device placement. Catheter ablation of the right ventricular outflow tract has been shown to reduce arrhythmic burden in selected patients with refractory disease and is being studied in larger trials.

CPVT (Catecholaminergic Polymorphic Ventricular Tachycardia)

CPVT is rarer than long QT or Brugada, with an estimated prevalence of around 1 in 10,000, but it's a especially dangerous channelopathy because the resting EKG is usually normal. Patients can be missed for years if the diagnosis isn't actively considered.

Genetics and Mechanism

About 50 to 60 percent of CPVT patients have a mutation in RYR2, the cardiac ryanodine receptor, which controls calcium release from the sarcoplasmic reticulum into the cytoplasm of cardiac myocytes. CASQ2 (cardiac calsequestrin) mutations account for a smaller fraction. The functional defect is excessive calcium release during adrenergic stimulation, which produces delayed afterdepolarizations that can trigger ventricular tachycardia. The trigger is always increased sympathetic tone, meaning exercise, emotional stress, or high catecholamine states.

Presentation

CPVT typically presents with exercise-induced or emotion-induced syncope or sudden death in children and young adults. The patient is usually otherwise healthy with a normal-looking heart on imaging and a normal resting EKG. The diagnosis is made by inducing the characteristic arrhythmia (bidirectional ventricular tachycardia or polymorphic VT) during exercise stress testing or, occasionally, during catecholamine challenge with isoproterenol or epinephrine.

Bidirectional VT, in which the QRS axis alternates beat to beat, is highly characteristic of CPVT, although it's also seen in digoxin toxicity and certain other conditions. The combination of bidirectional or polymorphic VT during exercise in a young patient with a normal-looking heart should always raise CPVT on the differential.

Family screening is important because the autosomal dominant inheritance pattern means siblings and children of an affected patient have a 50 percent chance of carrying the mutation. Cascade genetic testing in affected families identifies carriers who can then be evaluated and started on prophylactic treatment before they have a cardiac event.

Treatment

Beta-blocker therapy with nadolol is the foundation of CPVT treatment. Nadolol, dosed at roughly 1 to 2 mg per kilogram per day in adults, is more effective than other beta-blockers in this disease, probably because of its longer half-life and unique pharmacokinetic profile. Compliance is critical; missed doses can be the difference between safety and a sudden death event.

Flecainide added to a beta-blocker has been shown to reduce arrhythmic events in CPVT in patients with breakthrough events on beta-blocker alone. The mechanism is thought to involve direct inhibition of the abnormal RYR2 calcium leak. Combination therapy is now common in CPVT patients with any history of arrhythmic events.

An ICD is considered for CPVT patients who have had a cardiac arrest, who continue to have syncope despite optimal medical therapy, or who have very high-risk features. The complication is that an ICD shock in a CPVT patient can itself trigger a sympathetic surge that produces another VT episode, leading to electrical storm. ICD programming in CPVT requires careful attention, and some experienced centers recommend left cardiac sympathetic denervation as an alternative to ICD in selected patients.

Activity restriction is part of every CPVT plan. Competitive athletics are usually restricted, although moderate recreational exercise is permitted in most patients on optimized therapy. The exact restrictions are individualized based on disease severity, response to therapy, and the patient's risk tolerance.

Family Screening: The Underappreciated Value

All three channelopathies are inheritable, mostly in autosomal dominant patterns, which means first-degree relatives of an affected patient have roughly a 50 percent chance of carrying the same mutation. The clinical implication is enormous: when one patient is diagnosed, the entire family should be screened.

Cascade screening starts with the index patient (the proband). Once a mutation is identified in the proband, first-degree relatives are tested for that specific mutation. Carriers undergo clinical evaluation including EKG, echocardiogram, and exercise testing. Non-carriers are reassured and exited from cardiac surveillance. The yield is high because each generation of testing identifies additional family members who can be treated before they have an event.

Even in families where the proband doesn't have an identifiable genetic mutation, clinical screening of first-degree relatives with EKG and exercise testing is recommended for long QT and CPVT, since the genetic test sensitivity is not 100 percent and family screening can identify clinically affected relatives whose mutations aren't yet known.

When a patient comes in with a personal or family history of unexplained syncope, sudden cardiac death, drowning of a strong swimmer, or seizure-like episodes that might have been misdiagnosed, the channelopathy workup should be considered. The yield of finding a treatable diagnosis is meaningful, and the consequences of missing it are severe.

When to Suspect a Channelopathy

A channelopathy should be on the differential in several specific clinical scenarios.

Unexplained syncope, especially during exercise, during emotional stress, during sudden auditory stimuli, or during sleep. The temporal pattern of the syncope often points toward a specific channelopathy subtype.

Resuscitated cardiac arrest in a patient with a structurally normal heart on imaging. The full evaluation includes resting EKG, exercise testing, sometimes provocation testing with sodium channel blockers, and genetic testing.

Family history of unexplained sudden cardiac death in a young or middle-aged relative, especially if the death occurred during exercise, sleep, or following a sudden auditory stimulus.

Drowning of a known competent swimmer, especially without apparent reason. This is a classic LQT1 presentation that's sometimes attributed to swimming pool accidents when it should have triggered a channelopathy workup.

Seizure-like episodes that might be misdiagnosed epilepsy. Some channelopathy events present as a brief loss of consciousness with convulsive movements, which gets labeled as a seizure. The EKG and exercise testing can sort it out.

A coincidentally noted prolonged QT interval on a routine EKG done for some other reason, especially in a young patient.

When to Escalate Care

Call 911 immediately for cardiac arrest, sustained palpitations with lightheadedness or syncope, or any concern for a serious arrhythmia. Patients with known channelopathies should keep AEDs accessible at home and at work, and family members should be trained in CPR.

Contact your cardiologist the same day for new palpitations, presyncope, syncope without warning, or any concern about a missed dose of medication or a new prescription that might have QT-prolonging or sodium channel-blocking effects.

Schedule a clinic visit within one to two weeks for any concerns about activity restrictions, medication tolerability, or for routine follow-up. Patients with channelopathies benefit from a long-term relationship with a cardiologist who knows their specific disease and individual triggers.

Common Patient Questions

My EKG showed a slightly long QT. Should I worry?

It depends on how long, on whether it's reproducible, and on the clinical context. A QTc just over 440 milliseconds in someone with no symptoms and no family history is often unconcerning, sometimes the result of medications or electrolyte abnormalities. A QTc above 500 milliseconds, especially with a family history of sudden death or with a personal history of unexplained syncope, deserves a careful workup. The Schwartz score, exercise testing, and genetic testing help sort the question. The key is that an isolated long QT measurement is not the same as a long QT syndrome diagnosis, but it warrants consideration.

My brother died of unexplained sudden death at age 19. Should my children be screened?

Yes, this is exactly the kind of family history that warrants channelopathy screening. The workup typically includes a careful history (looking for clues about LQT versus Brugada versus CPVT triggers), a resting 12-lead EKG, an exercise stress test, and consideration of genetic testing if a specific channelopathy is suspected. Postmortem genetic testing of the deceased family member, when available, can identify the responsible mutation and simplify family screening. Even when the genetic etiology can't be confirmed, clinical evaluation of first-degree relatives can identify carriers and start them on protective therapy.

Why is nadolol used instead of metoprolol?

Nadolol has consistently shown better arrhythmic protection than other beta-blockers in long QT and CPVT. The mechanism is thought to involve longer half-life (which provides more steady protection through the day), more reliable beta-2 blockade (relevant in some long QT subtypes), and possibly direct effects on the underlying ion channel dysfunction. Atenolol and metoprolol are sometimes used when nadolol is unavailable or not tolerated, but nadolol is the first choice when it can be obtained.

I have Brugada syndrome and a fever. What should I do?

Treat the fever aggressively with acetaminophen. Fever can unmask the Type 1 EKG pattern and trigger arrhythmic events in Brugada patients. Acetaminophen at standard doses (1000 mg every six hours, not exceeding 4000 mg per day) is the first-line agent. NSAIDs are usually fine, but the priority is rapid temperature normalization. If you can't bring the fever down with oral medications, or if you have any palpitations, lightheadedness, or other concerning symptoms during the fever, get evaluated promptly. Many Brugada patients keep an EKG strip from a previous evaluation and can show it to the emergency department to expedite recognition.

Can I exercise with these conditions?

It depends on the specific diagnosis, the severity, and the response to treatment. LQT1 patients have the most restrictive recommendations, with avoidance of swimming alone, of competitive athletics, and sometimes of intense exercise in general. LQT2 and LQT3 patients can usually engage in moderate exercise with adequate beta-blockade. Brugada patients are usually allowed moderate aerobic exercise; competitive athletics are restricted in some cases but allowed in others. CPVT patients have major restrictions because their disease is exercise-triggered, with most competitive athletics avoided and recreational exercise modified. The exact recommendations come from a cardiologist familiar with the specific channelopathy and the individual patient.

Will I need an implantable defibrillator?

Some patients will, and some won't. Strong indications for an ICD include a history of resuscitated cardiac arrest, recurrent syncope despite optimal medication, and very high-risk genetic or clinical features. Patients without these features can often be managed safely with medication and lifestyle modification alone. The ICD decision involves balancing the protection against ventricular fibrillation against the lifelong implications of having a device, including potential complications, lead failures, inappropriate shocks, and the psychological adjustment. The decision is individualized.

Should I get genetic testing?

In most cases, yes. Genetic testing confirms the diagnosis when positive, identifies the specific subtype (which guides treatment), and enables cascade screening of family members. A negative test does not rule out the channelopathy clinically, but a positive test is highly informative. Modern genetic testing for channelopathies is more affordable than it used to be, and most insurance plans cover it when ordered with appropriate clinical justification. Genetic counseling, ideally with a cardiology genetic counselor, is part of the process and helps families understand the implications of the results.

A Final Note From Me

The channelopathies sit at the intersection of inherited disease, sudden cardiac death prevention, and family medicine. They reward clinical recognition because the diagnosis is usually clear once it's considered, the treatments are effective, and family screening can prevent additional events in relatives. The patients who do worst are the ones whose diagnosis is missed entirely or delayed for years. The patients who do best are the ones who get a clear diagnosis, an appropriate treatment plan, and a structured family screening cascade.

If you have a personal or family history that fits any of the patterns described in this article, please bring it up with your cardiologist or your primary care physician. Unexplained syncope during exercise, drowning of a competent swimmer, sudden death of a young relative, seizure-like episodes that don't fit a clear epilepsy pattern, or a slightly prolonged QT on a routine EKG are all reasons to ask whether a channelopathy workup is appropriate. The yield of finding something treatable is meaningful, and the cost of an EKG, an exercise test, or a genetic test is small compared to the cost of a missed diagnosis.

If you've been given a channelopathy diagnosis, partner with a cardiologist who has experience with the specific condition. Most cardiologists are familiar with these diseases in broad terms, but the management nuances (which beta-blocker, when to add flecainide, when to consider an ICD, how to handle pregnancy, what activities to allow) benefit from specialized expertise. Genetic counselors, electrophysiologists with channelopathy experience, and academic medical centers with dedicated programs can all add value to long-term care. The patients I'm hopeful about are the ones who built that team early and stayed engaged with it over time.

References

1. Ackerman, Michael J., Silvia G. Priori, Stephan Willems, et al. "HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies." Heart Rhythm 8, no. 8 (2011): 1308-1339.

2. Schwartz, Peter J., Lia Crotti, and Roberto Insolia. "Long-QT Syndrome: From Genetics to Management." Circulation: Arrhythmia and Electrophysiology 5, no. 4 (2012): 868-877.

3. Priori, Silvia G., Arthur A. M. Wilde, Minoru Horie, et al. "HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes." Heart Rhythm 10, no. 12 (2013): 1932-1963.

4. Mazzanti, Andrea, Alessandro Trancuccio, Deni Kukavica, et al. "Independent Validation and Clinical Implications of the Risk Prediction Model for Long QT Syndrome (1-2-3-LQTS-Risk)." Europace 24, no. 4 (2022): 614-619.

5. Brugada, Pedro, and Josep Brugada. "Right Bundle Branch Block, Persistent ST Segment Elevation and Sudden Cardiac Death: A Distinct Clinical and Electrocardiographic Syndrome." Journal of the American College of Cardiology 20, no. 6 (1992): 1391-1396.

6. Antzelevitch, Charles, Gan-Xin Yan, Michael J. Ackerman, et al. "J-Wave Syndromes Expert Consensus Conference Report." Heart Rhythm 13, no. 10 (2016): e295-e324.

7. Probst, Vincent, Christian Veltmann, Lars Eckardt, et al. "Long-Term Prognosis of Patients Diagnosed with Brugada Syndrome: Results from the FINGER Brugada Syndrome Registry." Circulation 121, no. 5 (2010): 635-643.

8. Leenhardt, Antoine, Vincent Lucet, Isabelle Denjoy, et al. "Catecholaminergic Polymorphic Ventricular Tachycardia in Children." Circulation 91, no. 5 (1995): 1512-1519.

9. van der Werf, Christian, Prince J. Kannankeril, Frederic Sacher, et al. "Flecainide Therapy Reduces Exercise-Induced Ventricular Arrhythmias in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia." Journal of the American College of Cardiology 57, no. 22 (2011): 2244-2254.

10. Hayashi, Meiso, Wataru Shimizu, and Christine M. Albert. "The Spectrum of Epidemiology Underlying Sudden Cardiac Death." Circulation Research 116, no. 12 (2015): 1887-1906.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.